Catalyst Dossier · compiled by CeliA 🧫

Zealand Pharma A/S (ZEAL)

Healthcare · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-31 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-10-31 (est.)Phase 3 · Glepaglutideimp 9/10

Pipeline

Asset	Phase	Indication
GlucaGen	Phase 3	Hypoglycemia
Petrelintide	Phase 2	Obesity
danegaptide	Phase 2	Focus of Study is STEMI
Glepaglutide	Phase 3	Short Bowel Syndrome
dasiglucagon	Phase 3	Hypoglycemia
ZP4207(dasiglucagon) glucagon analogue	Phase 2	Diabetes Mellitus Type 1
ZP1848	Phase 2	Short Bowel Syndrome
Insulin Lispro	Phase 2	Diabetes Mellitus, Type 1
ZP4207	Phase 2	Hypoglycemia

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ZEAL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.